Table 4. Sensitivity analysis using complete-case data.

	Colorectal cancer-specific survival					Overall survival
	Statin non-user	Statin user	HR (95%CI)a user vs non-user	P-value	P for interaction	Statin non-user	Statin user	HR (95%CI)b user vs non-user	P-value	P for interaction
	No. of deaths/patients					No. of deaths/patients
Overall
n=372	95/238	27/88	0.75 (0.48–1.20)	0.24	−	127/270	41/102	0.71 (0.47–1.06)	0.10	−
Stratified by patterns of p53 immunostaining
Normal	25/110	9/39	1.14 (0.48–2.72)	0.77	0.42	40/110	13/39	0.54 (0.22–1.30)	0.17	0.68
Aberrant	69/159	18/63	0.63 (0.36–1.11)	0.11		86/159	28/63	0.73 (0.45–1.18)	0.20
Stratified by HMGCR expression
H-score <median	48/138	14/40	0.92 (0.45–1.87)	0.82	0.05	71/138	18/40	0.56 (0.28–1.09)	0.09	0.32
H-score ⩾median	47/131	13/62	0.51 (0.26–0.97)	0.04		56/131	23/62	0.66 (0.39–1.14)	0.14
Stratified by KRAS mutation status
Wild-type	57/171	15/66	0.66 (0.34–1.28)	0.22	0.21	76/171	24/66	0.60 (0.34–1.05)	0.07	0.23
Mutated	38/99	12/36	1.14 (0.56–2.33)	0.72		51/99	17/36	0.91 (0.48–1.74)	0.78

Abbreviations: CI=confidence intervals; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; MSI=microsatellite instability.

^aMultivariable model adjusted for age, gender, year of diagnosis, grade, MSI status, ECOG performance status, family history of colorectal cancer, adjuvant chemotherapy use, stage, and aspirin use.

^bMultivariable model adjusted for all variables in footnote a and also adjusted for Charlson Comorbidity Index score.